Clinical trial
A Pilot Study of AZD9150, a STAT3 Antisense Oligonucleotide in Malignant Ascites
NCT02417753 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Pilot Study of AZD9150, a STAT3 Antisense Oligonucleotide in Malignant Ascites
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- April 3, 2015
- Completion date
- April 7, 2016
- Enrollment
- 1 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
ascites, gastrointestinal cancer, gastrointestinal neoplasms, ovarian cancer, ovarian neoplasms